U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07607938) titled 'Psilocybin as a Novel Therapy for Residual Anhedonia' on May 19.
Brief Summary: The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Anhedonia
Emotional Blunting
Intervention:
DRUG: Psilocybin
One-time dose of psilocyb...